EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gene Expression Analysis of Galectin-9, MALAT1, and ZAP-70 in Chronic Lymphocytic Leukemia and Their Diagnostic Potential: Association with Clinical Laboratory Features

Ayya J. Mohammed, Twana A. Mustafa

Zanco Journal of Pure and Applied Sciences · 30.06.2026 · 38 (3) · 1-13

DOI: 10.21271/zjpas.38.3.1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zanco Journal of Pure and Applied Sciences, online erschienen am 30.06.2026. Verfasst von Ayya J. Mohammed und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous B-cell malignancy where emerging molecular diagnostics offer potential improvements in diagnosis and prognostication. Recent evidence implicates Galectin-9, the long non-coding RNA MALAT1, and the tyrosine kinase-associated adaptor ZAP-70 in the pathophysiology and progression of CLL. This study aimed to quantitatively assess the transcriptional expression of these candidate biomarkers using quantitative real-time PCR (qRT-PCR) across three groups: treatment-naïve CLL, treated CLL, and healthy controls. A total of 59 Kurdish adults were enrolled and categorized into three groups: 12 newly diagnosed, treatment-naïve CLL patients; 27 CLL patients who had completed one line of therapy; and 20 healthy controls. Demographic and clinical data, including CBC parameters, flow cytometric immunophenotyping reports, in addition to cytological evaluation results that were performed using Leishman-stained peripheral blood smears, were collected. Total RNA was extracted from whole blood collected into EDTA tubes within 3–4 hours post-collection, followed by complementary DNA (cDNA) synthesis. Quantitative real-time PCR (qRT-PCR) was conducted to assess the transcriptional expression of Galectin-9, MALAT1, and ZAP-70, normalized to β-actin, across all samples. All three targets were significantly overexpressed in treated and Naïve CLL patients versus controls: Galectin-9 ΔCt: 5.31 ± 0.29 vs. 6.33 ± 0.11 (p = 0.0035); MALAT1 ΔCt: 1.50 ± 0.59 vs. 3.31 ± 0.14 (p = 0.0025); ZAP-70 ΔCt: 4.92 ± 0.66 vs. 7.52 ± 0.13 (p < 0.0001). ROC analysis showed strong discriminatory power for ZAP-70 (AUC = 0.89, p < 0.0001) and MALAT1 (AUC = 0.73, p = 0.003), with Galectin-9 demonstrating marginal significance (AUC = 0.64, p = 0.07). MALAT1 and ZAP-70 showed strong co-regulation (r = 0.64, p < 10⁻⁵) and were associated with several hematological parameters. These findings support the use of MALAT1 and ZAP-70 as minimally invasive biomarkers for CLL diagnosis and risk stratification, while Galectin-9 may reflect immune dysregulation.

Zitieren

APA

Mohammed, A. J., & Mustafa, T. A. (2026). Gene Expression Analysis of Galectin-9, MALAT1, and ZAP-70 in Chronic Lymphocytic Leukemia and Their Diagnostic Potential: Association with Clinical Laboratory Features. Zanco Journal of Pure and Applied Sciences, 38(3), 1-13. https://doi.org/10.21271/zjpas.38.3.1

Vancouver

Mohammed AJ, Mustafa TA. Gene Expression Analysis of Galectin-9, MALAT1, and ZAP-70 in Chronic Lymphocytic Leukemia and Their Diagnostic Potential: Association with Clinical Laboratory Features. Zanco Journal of Pure and Applied Sciences. 2026;38(3):1-13. doi:10.21271/zjpas.38.3.1

BibTeX
@article{Mohammed2026,
  author = {Mohammed, Ayya J. and Mustafa, Twana A.},
  title = {Gene Expression Analysis of Galectin-9, MALAT1, and ZAP-70 in Chronic Lymphocytic Leukemia and Their Diagnostic Potential: Association with Clinical Laboratory Features},
  journal = {Zanco Journal of Pure and Applied Sciences},
  year = {2026},
  volume = {38},
  number = {3},
  pages = {1--13},
  doi = {10.21271/zjpas.38.3.1}
}
Kostenlos starten →